Efficacy and safety of oral type II topoisomerase inhibitors versus ceftriaxone-based regimens for the treatment of gonorrhoea: A systematic review and meta-analysis of randomised controlled trials.
Husni Mubarak Zainal, Ricardo Soares Guimarães, Tanika Sharma et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy and safety of oral type II topoisomerase inhibitors, gepotidacin and zoliflodacin, compared to ceftriaxone for treating uncomplicated gonorrhoea. The analysis included data from three randomised controlled trials, revealing similar microbiological cure rates of 92% for topoisomerase inhibitors versus 94% for ceftriaxone, with no significant differences in adverse events.
Key findings
- Microbiological cure rates were 92% for topoisomerase inhibitors and 94% for ceftriaxone.
- No significant differences were found in cure rates across urogenital, rectal, or pharyngeal sites.
- Adverse events were similar between the two treatment groups.
- Confidence intervals for extragenital outcomes remained wide.
Why it matters
With rising antimicrobial resistance, exploring new treatment options for gonorrhoea is critical. This study suggests that oral topoisomerase inhibitors may be viable alternatives, although further research is necessary to establish their long-term effectiveness and safety.